Rasagiline treatment effects on parkinsonian tremor

References

• Fishman PS. Paradoxical aspects of parkinsonian tremor. Mov Disord 2008;23(2):168–73.
   PubMedGoogle Scholar
• Parkinson J. An essay on the shaking palsy. London: Sherwood, Neeley and Jones; 1817.
   Google Scholar
• Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79(4):368–76.
   PubMed Web of Science ®Google Scholar
• Helmich RC, Hallett M, Deuschl G, Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits? Brain 2012;135:3206–26.
   PubMed Web of Science ®Google Scholar
• Marjama-Lyons J, Koller W. Tremor-predominant Parkinson's disease. Approaches to treatment. Drugs Aging 2000;16(4):273–78.
   PubMed Web of Science ®Google Scholar
• Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol 2001;58(10):1611–5.
   PubMedGoogle Scholar
• Guillard A, Chastang C, Fenelon G. Long-term study of 416 cases of Parkinson disease. Prognostic factors and therapeutic implications. Rev Neurol (Paris) 1986;142(3):207–14.
   PubMedGoogle Scholar
• Saiki S, Sato S, Hattori N. Molecular pathogenesis of Parkinson's disease: update. J Neurol Neurosurg Psychiatry 2012;83(4):430–6.
   PubMed Web of Science ®Google Scholar
• Sung YH, Chung SJ, Kim SR, Lee MC. Factors predicting response to dopaminergic treatment for resting tremor of Parkinson's disease. Mov Disord 2008;23(1):137–40.
   PubMedGoogle Scholar
• Elble RJ. Tremor and dopamine agonists. Neurology 2002 26;58(4 Suppl 1):S57–62.
   Google Scholar
• Rascol O, Brooks DJ, Brunt ER, Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord 1998;13(1):39–45.
   PubMed Web of Science ®Google Scholar
• Politis M, Wu K, Molloy S, Parkinson's disease symptoms: the patient's perspective. Mov Disord 2010;15;25(11):1646–51.
   Google Scholar
• Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002;59(12):1937–43.
   PubMed Web of Science ®Google Scholar
• Olanow CW, Rascol O, Hauser R, A double-blind, delayed-start trial of rasagiline in Parkinson's disease. New Engl J Med 2009;361(13):1268–78.
   PubMed Web of Science ®Google Scholar
• Tolosa E, ADAGIO Investigators. Rasagiline improves key motor symptoms of Parkinson's disease in early stages: post-hoc analysis from the Attenuation of Disease progression with Azilect® Given Once-daily (ADAGIO) study. (Abstract P2600) Eur J Neurol 2012;19(Suppl 1):657.
   Google Scholar
• Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62(2):241–8.
   PubMed Web of Science ®Google Scholar
• Rascol O, Brooks DJ, Melamed E, Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365(9463): 947–54.
   PubMed Web of Science ®Google Scholar
• Bertoni J, Pahwa R. Rasagiline is effective in treating patients with early Parkinson's disease, regardless of disease duration at treatment initiation (<1 year; > = 1 year). Poster session presented at: Movement Disorder Society's 11th International Congress; 2007 June 3–7; Instanbul, Turkey.
   Google Scholar
• Rascol O, Brooks DJ, Melamed E, Effect of rasagiline on tremor in levodopa-treated Parkinson's disease patients (LARGO study). Poster session presented at: The 8th Congress of the European Federation of Neurological Societies; 2004 September 4–7; Paris, France.
   Google Scholar
• Rabey JM, Fitzer-Attas CJ. Effect of adjunct rasagiline on dopaminergic and non-dopaminergic motor featurs of Parkinson's disease. Poster session presented at: Movement Disorder Society's 11th International Congress; 2007 June 3–7; Instanbul, Turkey.
   Google Scholar
• Schwid SR, The PRESTO and LARGO Investigators. Once-daily rasagiline produces consistent treatment benefits in US and European studies of Parkinson's disease patients. Poster session presented at: The 131st Annual Meeting of the American Neurological Association; 2006 October 8–11; Chicago, Illinois.
   Google Scholar
• Pogarell O, Gasser T, van Hilten JJ, Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 2002;72(6):713–20.
   PubMed Web of Science ®Google Scholar
• Elmer L, Schwid S, Eberly S, Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci 2006;248:78–83.
   PubMed Web of Science ®Google Scholar
• Tarrants ML, Denarie MF, Castelli-Haley J, Drug therapies for Parkinson's disease: a database analysis of patient compliance and persistence. Am J Geriatr Pharmacother 2010;8(4):374–83.
   PubMed Web of Science ®Google Scholar
• Carr J. Tremor in Parkinson's disease. Parkinsonism Relat Disord 2002;8(4):223–34.
   PubMedGoogle Scholar
• Lenz FA, Vitek JL, DeLong MR. Role of the thalamus in parkinsonian tremor: evidence from studies in patients and primate models. Stereotact Funct Neurosurg 1993;60(1–3):94–103.
   PubMedGoogle Scholar
• Zaidel A, Arkadir D, Israel Z, Bergman H. Akineto-rigid vs. tremor syndromes in Parkinsonism. Curr Opin Neurol 2009;22(4):387–93.
   PubMedGoogle Scholar
• Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991;50(6):743–55.
   PubMed Web of Science ®Google Scholar
• Benninger DH, Thees S, Kollias SS, Morphological differences in Parkinson's disease with and without rest tremor. J Neurol 2009;256(2):256–63.
   PubMedGoogle Scholar
• Pirker W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord 2003;18(Suppl 7):S43–51.
   Google Scholar
• Benamer HT, Oertel WH, Patterson J, Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations. Mov Disord 2003;18(9): 977–84.
   PubMedGoogle Scholar
• Doder M, Rabiner EA, Turjanski N, Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 2003;25;60(4): 601–5.
   Google Scholar
• Timmermann L, Florin E, Reck C. Pathological cerebral oscillatory activity in Parkinson's disease: a critical review on methods, data and hypotheses. Expert Rev Med Devices 2007;4(5):651–61.
   PubMed Web of Science ®Google Scholar
• Martin WE, Lowenson RB, Resch JA, A controlled study comparing trihexyphenidyl hydrochloride plus levodopa with placebo plus levodopa in patients with Parkinson's disease. Neurology 1974;24:912–9.
   PubMed Web of Science ®Google Scholar
• Koller WC. Pharmacologic treatment of parkinsonian tremor. Arch Neurol 1986;43:126–7.
   PubMedGoogle Scholar
• Reichmann H, Jost WH. Efficacy and tolerability of rasagiline in daily clinical use –a post-marketing observational study in patients with Parkinson's disease. Eur J Neurol 2010;17(9):1164–71.
   PubMed Web of Science ®Google Scholar
• Biglan KM, Schwid S, Eberly S, Rasagiline improves quality of life in patients with early Parkinson's disease. Mov Disord 2006;21(5):616–23.
   PubMed Web of Science ®Google Scholar